| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| BWAYBrainsWay Ltd. | 452.42M | 23.10 | 128.33 | 29.04% | 12.73% | 8.92% | 1.44% | 0.09 |
| INSPInspire Medical Systems, Inc. | 2.8B | 96.47 | 55.13 | 28.49% | 5.05% | 6.69% | 3.25% | 0.05 |
| TIVCTivic Health Systems, Inc. | 3.11M | 1.23 | -0.06 | -33.67% | -15.57% | -134.25% | ||
| COCHEnvoy Medical, Inc. | 19.42M | 0.67 | -0.45 | -28.8% | -104.75% | |||
| HSDTSolana Company | 128.03M | 3.10 | -0.72 | -19.25% | -393.59% | -6.89% | 0.01 | |
| NXLNexalin Technology, Inc. | 12.87M | 0.69 | -0.83 | 52.35% | -55.3% | -182.01% | ||
| CVRXCVRx, Inc. | 143.37M | 5.47 | -2.06 | 30.53% | -92.95% | -108.26% | 0.71 | |
| VANIVivani Medical, Inc. | 91.92M | 1.26 | -2.93 | -19.88% | 1.10 |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 16.43M | 28.57M | 50.59M | 82.05M | 115.38M | 233.39M | 407.86M | 624.8M | 802.8M |
| Revenue Growth % | - | 0.74% | 0.77% | 0.62% | 0.41% | 1.02% | 0.75% | 0.53% | 0.28% |
| Cost of Goods Sold | 3.9M | 6.02M | 10.06M | 13.64M | 17.62M | 33.28M | 66.11M | 96.58M | 122.99M |
| COGS % of Revenue | 0.24% | 0.21% | 0.2% | 0.17% | 0.15% | 0.14% | 0.16% | 0.15% | 0.15% |
| Gross Profit | 12.52M | 22.55M | 40.54M | 68.41M | 97.76M | 200.12M | 341.74M | 528.22M | 679.82M |
| Gross Margin % | 0.76% | 0.79% | 0.8% | 0.83% | 0.85% | 0.86% | 0.84% | 0.85% | 0.85% |
| Gross Profit Growth % | - | 0.8% | 0.8% | 0.69% | 0.43% | 1.05% | 0.71% | 0.55% | 0.29% |
| Operating Expenses | 29.77M | 38.55M | 60.91M | 103.3M | 153.97M | 239.97M | 389.33M | 568.49M | 643.74M |
| OpEx % of Revenue | 1.81% | 1.35% | 1.2% | 1.26% | 1.33% | 1.03% | 0.95% | 0.91% | 0.8% |
| Selling, General & Admin | 22.68M | 32.36M | 53.53M | 90.47M | 127.87M | 202.62M | 320.69M | 451.96M | 529.61M |
| SG&A % of Revenue | 1.38% | 1.13% | 1.06% | 1.1% | 1.11% | 0.87% | 0.79% | 0.72% | 0.66% |
| Research & Development | 7.09M | 6.19M | 7.39M | 12.84M | 26.09M | 37.35M | 68.64M | 116.54M | 114.13M |
| R&D % of Revenue | 0.43% | 0.22% | 0.15% | 0.16% | 0.23% | 0.16% | 0.17% | 0.19% | 0.14% |
| Other Operating Expenses | -29K | 42K | -16K | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -17.25M | -16M | -20.38M | -34.9M | -56.21M | -39.85M | -47.59M | -40.27M | 36.08M |
| Operating Margin % | -1.05% | -0.56% | -0.4% | -0.43% | -0.49% | -0.17% | -0.12% | -0.06% | 0.04% |
| Operating Income Growth % | - | 0.07% | -0.27% | -0.71% | -0.61% | 0.29% | -0.19% | 0.15% | 1.9% |
| EBITDA | -17.15M | -15.72M | -19.98M | -34.4M | -55.37M | -38.63M | -45.73M | -37.42M | 42.63M |
| EBITDA Margin % | -1.04% | -0.55% | -0.4% | -0.42% | -0.48% | -0.17% | -0.11% | -0.06% | 0.05% |
| EBITDA Growth % | - | 0.08% | -0.27% | -0.72% | -0.61% | 0.3% | -0.18% | 0.18% | 2.14% |
| D&A (Non-Cash Add-back) | 103K | 285K | 393K | 495K | 840K | 1.22M | 1.86M | 2.85M | 6.55M |
| EBIT | -17.23M | -15.76M | -18.52M | -31.08M | -54.97M | -39.84M | -42.59M | -19.91M | 58.48M |
| Net Interest Income | -1.25M | -1.55M | -1.43M | 1.68M | -1.02M | -2M | 3.37M | 20.56M | 23.23M |
| Interest Income | 57K | 203K | 1.87M | 3.8M | 1.09M | 125K | 5.05M | 20.56M | 23.25M |
| Interest Expense | 1.3M | 1.75M | 3.3M | 2.12M | 2.12M | 2.13M | 1.68M | 0 | 22K |
| Other Income/Expense | -1.27M | -1.51M | -1.45M | 1.69M | -880K | -2.12M | 3.32M | 20.36M | 22.37M |
| Pretax Income | -18.53M | -17.51M | -21.83M | -33.2M | -57.09M | -41.97M | -44.27M | -19.91M | 58.45M |
| Pretax Margin % | -1.13% | -0.61% | -0.43% | -0.4% | -0.49% | -0.18% | -0.11% | -0.03% | 0.07% |
| Income Tax | 0 | 0 | 0 | 40K | 115K | 72K | 613K | 1.25M | 4.94M |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1.01% | 1.06% | 0.92% |
| Net Income | -18.53M | -17.51M | -21.83M | -33.24M | -57.2M | -42.04M | -44.88M | -21.15M | 53.51M |
| Net Margin % | -1.13% | -0.61% | -0.43% | -0.41% | -0.5% | -0.18% | -0.11% | -0.03% | 0.07% |
| Net Income Growth % | - | 0.05% | -0.25% | -0.52% | -0.72% | 0.27% | -0.07% | 0.53% | 3.53% |
| Net Income (Continuing) | -18.53M | -17.51M | -21.83M | -33.24M | -57.2M | -42.04M | -44.88M | -21.15M | 53.51M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.49 | -1.30 | -1.50 | -1.40 | -2.19 | -1.54 | -1.60 | -0.72 | 1.75 |
| EPS Growth % | - | 0.13% | -0.15% | 0.07% | -0.56% | 0.3% | -0.04% | 0.55% | 3.43% |
| EPS (Basic) | -1.49 | -1.30 | -1.50 | -1.40 | -2.19 | -1.54 | -1.60 | -0.72 | 1.80 |
| Diluted Shares Outstanding | 12.46M | 13.49M | 14.58M | 23.8M | 26.07M | 27.26M | 28.07M | 29.3M | 30.54M |
| Basic Shares Outstanding | 12.46M | 13.49M | 14.58M | 23.8M | 26.07M | 27.26M | 28.07M | 29.3M | 29.76M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 12.25M | 24.1M | 199.28M | 170.64M | 269.87M | 268.54M | 530.03M | 593.74M | 630.81M |
| Cash & Short-Term Investments | 6.68M | 16.14M | 188.21M | 149.47M | 234.36M | 214.47M | 451.41M | 460.38M | 445.55M |
| Cash Only | 6.68M | 8.96M | 97.29M | 22.86M | 190.52M | 214.47M | 441.59M | 185.54M | 150.15M |
| Short-Term Investments | 0 | 7.19M | 90.92M | 126.61M | 43.84M | 0 | 9.82M | 274.84M | 295.4M |
| Accounts Receivable | 2.09M | 3.86M | 6.67M | 13.13M | 25.06M | 34.18M | 61.23M | 89.88M | 93.07M |
| Days Sales Outstanding | 46.46 | 49.29 | 48.1 | 58.41 | 79.29 | 53.45 | 54.79 | 52.51 | 42.31 |
| Inventory | 3.35M | 3.67M | 2.67M | 5.83M | 8.48M | 17.23M | 11.89M | 33.88M | 80.12M |
| Days Inventory Outstanding | 313.59 | 222.59 | 96.8 | 156.08 | 175.61 | 188.99 | 65.62 | 128.07 | 237.78 |
| Other Current Assets | 118K | 426K | 1.73M | 0 | 0 | 0 | 5.5M | 9.6M | 12.07M |
| Total Non-Current Assets | 867K | 994K | 802K | 10.62M | 11.32M | 26.55M | 34.84M | 83.07M | 177.58M |
| Property, Plant & Equipment | 867K | 994K | 802K | 3.96M | 11.12M | 16.41M | 24.13M | 62.65M | 95.24M |
| Fixed Asset Turnover | 18.95x | 28.74x | 63.08x | 20.72x | 10.38x | 14.23x | 16.90x | 9.97x | 8.43x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 6.28M | 0 | 9.94M | 0 | 9.14M | 71M |
| Other Non-Current Assets | 0 | 0 | 0 | 381K | 204K | 204K | 10.71M | 11.28M | 11.34M |
| Total Assets | 13.12M | 25.09M | 200.08M | 181.25M | 281.19M | 295.08M | 564.88M | 676.81M | 808.38M |
| Asset Turnover | 1.25x | 1.14x | 0.25x | 0.45x | 0.41x | 0.79x | 0.72x | 0.92x | 0.99x |
| Asset Growth % | - | 0.91% | 6.97% | -0.09% | 0.55% | 0.05% | 0.91% | 0.2% | 0.19% |
| Total Current Liabilities | 7.29M | 7.15M | 11.15M | 16.86M | 20.73M | 41.31M | 61.19M | 78.11M | 88.5M |
| Accounts Payable | 1.17M | 3M | 3.43M | 4.46M | 7.21M | 11.66M | 26.85M | 38.84M | 38.69M |
| Days Payables Outstanding | 109.64 | 181.83 | 124.46 | 119.29 | 149.31 | 127.94 | 148.21 | 146.79 | 114.82 |
| Short-Term Debt | 3.31M | 0 | 0 | 0 | 0 | 9.19M | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 382K | 555K | 1.24M | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Ratio | 1.68x | 3.37x | 17.86x | 10.12x | 13.02x | 6.50x | 8.66x | 7.60x | 7.13x |
| Quick Ratio | 1.22x | 2.86x | 17.63x | 9.78x | 12.61x | 6.08x | 8.47x | 7.17x | 6.22x |
| Cash Conversion Cycle | 250.41 | 90.05 | 20.44 | 95.2 | 105.59 | 114.5 | -27.8 | 33.79 | 165.27 |
| Total Non-Current Liabilities | 12.43M | 16.62M | 24.93M | 24.56M | 30.72M | 24.73M | 7.68M | 26.19M | 30.19M |
| Long-Term Debt | 12.38M | 16.46M | 24.93M | 24.52M | 24.75M | 15.8M | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 5.89M | 8.8M | 7.54M | 24.85M | 30.04M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 53K | 157K | 0 | 40K | 85K | 134K | 146K | 1.35M | 148K |
| Total Liabilities | 19.72M | 23.61M | 36.08M | 41.42M | 51.44M | 66.04M | 68.87M | 104.3M | 118.69M |
| Total Debt | 15.69M | 16.46M | 24.93M | 25.35M | 30.63M | 34.09M | 8.87M | 24.85M | 31.79M |
| Net Debt | 9.01M | 7.5M | -72.36M | 2.49M | -159.89M | -180.37M | -432.72M | -160.69M | -118.36M |
| Debt / Equity | - | 11.09x | 0.15x | 0.18x | 0.13x | 0.15x | 0.02x | 0.04x | 0.05x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | 0.75x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | -2.78x |
| Interest Coverage | -13.24x | -9.13x | -6.17x | -16.47x | -26.55x | -18.73x | -28.38x | - | 1640.14x |
| Total Equity | -6.61M | 1.48M | 164M | 139.84M | 229.75M | 229.05M | 496.01M | 572.51M | 689.7M |
| Equity Growth % | - | 1.22% | 109.51% | -0.15% | 0.64% | -0% | 1.17% | 0.15% | 0.2% |
| Book Value per Share | -0.53 | 0.11 | 11.25 | 5.87 | 8.81 | 8.40 | 17.67 | 19.54 | 22.58 |
| Total Shareholders' Equity | -6.61M | 1.48M | 164M | 139.84M | 229.75M | 229.05M | 496.01M | 572.51M | 689.7M |
| Common Stock | 1K | 13K | 23K | 24K | 27K | 27K | 29K | 30K | 30K |
| Retained Earnings | -107.57M | -125.08M | -146.91M | -180.16M | -237.35M | -279.39M | -324.27M | -345.42M | -291.91M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | -52K | 102K | 29K | -55K | -86K | 800K | 536K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -17.95M | -15.79M | -18.69M | -32.85M | -53.05M | -20.12M | 11.57M | 24.65M | 130.25M |
| Operating CF Margin % | -1.09% | -0.55% | -0.37% | -0.4% | -0.46% | -0.09% | 0.03% | 0.04% | 0.16% |
| Operating CF Growth % | - | 0.12% | -0.18% | -0.76% | -0.61% | 0.62% | 1.58% | 1.13% | 4.28% |
| Net Income | -18.53M | -17.51M | -21.83M | -33.24M | -57.2M | -42.04M | -44.88M | -21.15M | 53.51M |
| Depreciation & Amortization | 103K | 285K | 393K | 495K | 840K | 1.22M | 1.86M | 2.85M | 6.55M |
| Stock-Based Compensation | 248K | 243K | 1.22M | 6.2M | 12.82M | 26.48M | 51.97M | 82.47M | 116.01M |
| Deferred Taxes | -195K | 100K | -53K | 0 | -22K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 180K | 315K | 714K | 279K | 1.4M | 5.86M | 15.17M | 1.27M | -7.51M |
| Working Capital Changes | 243K | 777K | 861K | -6.57M | -10.88M | -11.63M | -12.54M | -40.78M | -38.31M |
| Change in Receivables | -760K | -1.77M | -2.84M | -6.48M | -11.84M | -9.24M | -27.02M | -30.22M | -2.6M |
| Change in Inventory | 612K | -315K | 1M | -3.17M | -2.65M | -8.75M | 5.34M | -22M | -46.23M |
| Change in Payables | -480K | 1.82M | 439K | 1.03M | 2.05M | 0 | 0 | 9.3M | 0 |
| Cash from Investing | -306K | -7.6M | -83.39M | -43.56M | 86.63M | 29.14M | -19.6M | -294.82M | -113.12M |
| Capital Expenditures | -306K | -412K | -250K | -2.74M | -2.46M | -4.67M | -9.1M | -23.63M | -39.12M |
| CapEx % of Revenue | 0.02% | 0.01% | 0% | 0.03% | 0.02% | 0.02% | 0.02% | 0.04% | 0.05% |
| Acquisitions | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -7.19M | -83.14M | 0 | 89.08M | 33.81M | -10.5M | 0 | -74M |
| Cash from Financing | 12.81M | 25.66M | 190.38M | 1.96M | 134.06M | 14.95M | 235.08M | 13.95M | -52.39M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - |
| Other Financing | 466K | 235K | 558K | 1.96M | 9.41M | 14.95M | 259.62M | 13.95M | 27.77M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -18.25M | -16.2M | -18.94M | -35.59M | -55.5M | -24.79M | 2.47M | 1.02M | 91.12M |
| FCF Margin % | -1.11% | -0.57% | -0.37% | -0.43% | -0.48% | -0.11% | 0.01% | 0% | 0.11% |
| FCF Growth % | - | 0.11% | -0.17% | -0.88% | -0.56% | 0.55% | 1.1% | -0.59% | 87.99% |
| FCF per Share | -1.46 | -1.20 | -1.30 | -1.49 | -2.13 | -0.91 | 0.09 | 0.03 | 2.98 |
| FCF Conversion (FCF/Net Income) | 0.97x | 0.90x | 0.86x | 0.99x | 0.93x | 0.48x | -0.26x | -1.17x | 2.43x |
| Interest Paid | 0 | 0 | 0 | 2.03M | 0 | 1.89M | 2.32M | 0 | 22K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -1179.99% | -26.38% | -21.88% | -30.96% | -18.33% | -12.38% | -3.96% | 8.48% |
| Return on Invested Capital (ROIC) | - | -210.81% | -30.38% | -22.37% | -39.73% | -50.43% | -63.76% | -12.71% | 5.51% |
| Gross Margin | 76.23% | 78.93% | 80.12% | 83.37% | 84.73% | 85.74% | 83.79% | 84.54% | 84.68% |
| Net Margin | -112.79% | -61.3% | -43.14% | -40.52% | -49.58% | -18.01% | -11% | -3.39% | 6.67% |
| Debt / Equity | - | 11.09x | 0.15x | 0.18x | 0.13x | 0.15x | 0.02x | 0.04x | 0.05x |
| Interest Coverage | -13.24x | -9.13x | -6.17x | -16.47x | -26.55x | -18.73x | -28.38x | - | 1640.14x |
| FCF Conversion | 0.97x | 0.90x | 0.86x | 0.99x | 0.93x | 0.48x | -0.26x | -1.17x | 2.43x |
| Revenue Growth | - | 73.9% | 77.1% | 62.18% | 40.62% | 102.28% | 74.75% | 53.19% | 28.49% |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Operating | - | - | - | - | - | - | 802.8M |
| Operating Growth | - | - | - | - | - | - | - |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 44.38M | 73.66M | 106.11M | 220.98M | 394.83M | 606.18M | 771.04M |
| UNITED STATES Growth | - | 65.98% | 44.05% | 108.26% | 78.68% | 53.53% | 27.20% |
| Non-US | - | - | - | - | - | - | 31.76M |
| Non-US Growth | - | - | - | - | - | - | - |
| All Other Countries | - | - | - | 12.42M | 13.02M | 18.62M | - |
| All Other Countries Growth | - | - | - | - | 4.87% | 42.99% | - |
| Europe | 6.21M | 8.39M | 9.27M | - | - | - | - |
| Europe Growth | - | 35.00% | 10.52% | - | - | - | - |
Inspire Medical Systems, Inc. (INSP) has a price-to-earnings (P/E) ratio of 55.1x. This suggests investors expect higher future growth.
Inspire Medical Systems, Inc. (INSP) reported $882.6M in revenue for fiscal year 2024. This represents a 5273% increase from $16.4M in 2016.
Inspire Medical Systems, Inc. (INSP) grew revenue by 28.5% over the past year. This is strong growth.
Yes, Inspire Medical Systems, Inc. (INSP) is profitable, generating $44.6M in net income for fiscal year 2024 (6.7% net margin).
Inspire Medical Systems, Inc. (INSP) has a return on equity (ROE) of 8.5%. This is below average, suggesting room for improvement.
Inspire Medical Systems, Inc. (INSP) generated $98.8M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.